Literature DB >> 1733747

Preliminary assessment of the efficacy of Org 6370 in photosensitive epileptic patients: paradoxical enhancement of photosensitivity and provocation of myoclonic seizures.

D G Kasteleijn-Nolst Trenité1, W van Emde Boas, C M Groenhout, H Meinardi.   

Abstract

Photosensitivity has proved to be a useful model to study the acute effects of experimental antiepileptic drugs (AEDs). The photosensitivity range is usually diminished or even abolished after administration of a known or experimental AED. An increase in photosensitivity, an unexpected reaction, was found in four photosensitive epileptic patients after oral ingestion of 500, 100, or 50 mg of Org 6370. Moreover, the three patients receiving doses of 100 and 500 mg reported nausea, dizziness, restlessness, and an increase in spontaneous epileptic seizures (myoclonus and in one patient a generalized tonic-clonic convulsion). The side effects coincided with peak Org 6370 serum levels. Our findings indicate that in the photosensitivity model experimental drugs with proven anticonvulsant properties in animals may increase rather than decrease the degree of patient photosensitivity. Photosensitive patients may represent a special subgroup of epileptic patients and therefore need to be classified as such.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733747     DOI: 10.1111/j.1528-1157.1992.tb02296.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

Review 1.  Evaluation of drug treatment outcome in epilepsy: a clinical perspective.

Authors:  E Perucca
Journal:  Pharm World Sci       Date:  1997-10

2.  Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocol.

Authors:  Jacqueline A French; Gregory L Krauss; Dorothee Kasteleijn; Bree D DiVentura; Emilia Bagiella
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

3.  Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089).

Authors:  Dorothee G A Kasteleijn-Nolst Trenite; Bree D DiVentura; John R Pollard; Gregory L Krauss; Sarah Mizne; Jacqueline A French
Journal:  Neurology       Date:  2019-07-10       Impact factor: 9.910

4.  Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy.

Authors:  Dorotheé G A Kasteleijn-Nolst Trenité; Victor Biton; Jacqueline A French; Bassel Abou-Khalil; William E Rosenfeld; Bree Diventura; Elizabeth L Moore; Seth V Hetherington; Greg C Rigdon
Journal:  Epilepsia       Date:  2013-05-20       Impact factor: 5.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.